Nucleoside aryl phosphoramidates and their use as anti-viral agents for the treatment of hepatitis C virus
US8658616B2 · kind B2 · utility
43Cited by
15References
22Claims
0Family size
Assignees
Inventors
Key dates
| Filing date | Nov 23, 2007 |
| Grant date | Feb 25, 2014 |
| Priority date | — |
| Expiry date | Jun 27, 2029 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61P31/14
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Compounds having the general formula (I):are provided which have enhanced inhibitory potency and are thus useful in methods of prophylaxis or treatment of a viral infection such as hepatitis C virus. The compounds are phosphoramidate derivatives of nucleoside compounds derived from bases such as adenine and guanine. The glycoside moiety of the nucleoside compound can be substituted at the ss-2′ position with methyl and the phosphoramidate group can be 1-naphthyl linked by —O— to the P atom. These compounds can be administered as pharmaceutical compositions, and methods for their preparation are also provided.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.